Literature DB >> 36149537

Recurrent macrophage activation syndrome due to hyperimmunoglobulin D syndrome: a case-based review.

Deniz Gezgin Yıldırım1, Çisem Yıldız Yıldırım2, Nihal Karaçayır2, Pelin Esmeray Şenol2, Emine Nur Sunar Yayla2, Sevcan A Bakkaloğlu2.   

Abstract

Hyperimmunoglobulin D syndrome (HIDS) is a hereditary autoinflammatory disease characterized by recurrent inflammatory attacks with fever, abdominal pain, lymphadenopathy, aphthous stomatitis, and skin lesions. There are few reports on HIDS patients complicated with macrophage activation syndrome (MAS); however, to our knowledge, there is no case of HIDS with recurrent MAS attacks. We report two pediatric patients initially diagnosed as Kawasaki disease and systemic juvenile idiopathic arthritis presented with recurrent MAS episodes with prolonged fever, skin rash, hepatosplenomegaly, cervical lymphadenopathy, aphthous stomatitis, headache, pancytopenia, hyperferritinemia, and hypofibrinogenemia, finally diagnosed as HIDS with a documented homozygous MVK gene mutation. This is the first report on recurrent MAS attacks due to HIDS in pediatric patients who were successful treated with corticosteroids and anti-IL-1 therapies. Thus, clinicians should be vigilantly investigated signs of autoinflammatory diseases in patients with recurrent MAS attacks during their disease course, and HIDS should be considered an underlying disease for triggering recurrent MAS attacks. We have also reviewed the current literature regarding HIDS cases complicated with a MAS attack and summarized their demographic, treatment, and outcome characteristics. Key points • Hyperimmunoglobulin D syndrome should be considered in differential diagnosis in patients who experienced recurrent macrophage activation syndrome attacks.
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Anakinra; Canakinumab; Hyperimmunoglobulin D syndrome; Macrophage activation syndrome; Mevalonate kinase deficiency

Year:  2022        PMID: 36149537     DOI: 10.1007/s10067-022-06384-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  20 in total

1.  Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome.

Authors:  Donato Rigante; Valentina Ansuini; Barbara Bertoni; Anna Lisa Pugliese; Laura Avallone; Gilda Federico; Achille Stabile
Journal:  Rheumatol Int       Date:  2006-07-27       Impact factor: 2.631

Review 2.  Recommendations for the management of autoinflammatory diseases.

Authors:  Nienke M ter Haar; Marlen Oswald; Jerold Jeyaratnam; Jordi Anton; Karyl S Barron; Paul A Brogan; Luca Cantarini; Caroline Galeotti; Gilles Grateau; Veronique Hentgen; Michael Hofer; Tilmann Kallinich; Isabelle Kone-Paut; Helen J Lachmann; Huri Ozdogan; Seza Ozen; Ricardo Russo; Anna Simon; Yosef Uziel; Carine Wouters; Brian M Feldman; Sebastiaan J Vastert; Nico M Wulffraat; Susanne M Benseler; Joost Frenkel; Marco Gattorno; Jasmin B Kuemmerle-Deschner
Journal:  Ann Rheum Dis       Date:  2015-06-24       Impact factor: 19.103

3.  Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group.

Authors:  J P Drenth; L Cuisset; G Grateau; C Vasseur; S D van de Velde-Visser; J G de Jong; J S Beckmann; J W van der Meer; M Delpech
Journal:  Nat Genet       Date:  1999-06       Impact factor: 38.330

4.  Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience.

Authors:  Kenan Barut; Amra Adrovic; Sezgin Sahin; Gurkan Tarcin; Gulberk Tahaoglu; Oya Koker; Mehmet Yildiz; Ozgur Kasapcopur
Journal:  Int J Rheum Dis       Date:  2019-07-04       Impact factor: 2.454

Review 5.  A Comprehensive Overview of the Hereditary Periodic Fever Syndromes.

Authors:  Donato Rigante; Bruno Frediani; Luca Cantarini
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

Review 6.  Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options.

Authors:  Ellen Brisse; Patrick Matthys; Carine H Wouters
Journal:  Br J Haematol       Date:  2016-06-12       Impact factor: 6.998

7.  Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome.

Authors:  Kazuki Takada; Ivona Aksentijevich; Vijayabhanu Mahadevan; Jane A Dean; Richard I Kelley; Daniel L Kastner
Journal:  Arthritis Rheum       Date:  2003-09

8.  Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.

Authors:  Selin Aytaç; Ezgi Deniz Batu; Şule Ünal; Yelda Bilginer; Mualla Çetin; Murat Tuncer; Fatma Gümrük; Seza Özen
Journal:  Rheumatol Int       Date:  2016-08-10       Impact factor: 2.631

Review 9.  IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives.

Authors:  Hana Malcova; Zuzana Strizova; Tomas Milota; Ilja Striz; Anna Sediva; Dita Cebecauerova; Rudolf Horvath
Journal:  Front Immunol       Date:  2021-02-01       Impact factor: 7.561

Review 10.  Natural history of mevalonate kinase deficiency: a literature review.

Authors:  Shumin Zhang
Journal:  Pediatr Rheumatol Online J       Date:  2016-05-04       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.